BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 28215900)

  • 1. Lack of Early Improvement with Antipsychotics is a Marker for Subsequent Nonresponse in Behavioral and Psychological Symptoms of Dementia: Analysis of CATIE-AD Data.
    Yoshida K; Roberts R; Suzuki T; Lebowitz B; Reeves S; Howard R; Abe T; Mimura M; Uchida H
    Am J Geriatr Psychiatry; 2017 Jul; 25(7):708-716. PubMed ID: 28215900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Placebo Effects in the Treatment of Noncognitive Symptoms of Alzheimer's Disease: Analysis of the CATIE-AD Data.
    Ozawa C; Roberts R; Yoshida K; Suzuki T; Lebowitz B; Reeves S; Howard R; Abe T; Mimura M; Uchida H
    J Clin Psychiatry; 2017; 78(9):e1204-e1210. PubMed ID: 29045769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.
    Sultzer DL; Davis SM; Tariot PN; Dagerman KS; Lebowitz BD; Lyketsos CG; Rosenheck RA; Hsiao JK; Lieberman JA; Schneider LS;
    Am J Psychiatry; 2008 Jul; 165(7):844-54. PubMed ID: 18519523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Improvements of Individual Symptoms With Antipsychotics Predict Subsequent Treatment Response of Neuropsychiatric Symptoms in Alzheimer's Disease: A Re-Analysis of the CATIE-AD Study.
    Nagata T; Shinagawa S; Yoshida K; Noda Y; Shigeta M; Mimura M; Nakajima S
    J Clin Psychiatry; 2020 Feb; 81(2):. PubMed ID: 32074412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.
    Vigen CL; Mack WJ; Keefe RS; Sano M; Sultzer DL; Stroup TS; Dagerman KS; Hsiao JK; Lebowitz BD; Lyketsos CG; Tariot PN; Zheng L; Schneider LS
    Am J Psychiatry; 2011 Aug; 168(8):831-9. PubMed ID: 21572163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
    Daiello LA
    Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD).
    Gareri P; Cotroneo A; Lacava R; Seminara G; Marigliano N; Loiacono A; De Sarro G
    Arch Gerontol Geriatr Suppl; 2004; (9):207-15. PubMed ID: 15207416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
    Schneider LS; Tariot PN; Dagerman KS; Davis SM; Hsiao JK; Ismail MS; Lebowitz BD; Lyketsos CG; Ryan JM; Stroup TS; Sultzer DL; Weintraub D; Lieberman JA;
    N Engl J Med; 2006 Oct; 355(15):1525-38. PubMed ID: 17035647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.
    Nakajima S; Takeuchi H; Fervaha G; Plitman E; Chung JK; Caravaggio F; Iwata Y; Mihashi Y; Gerretsen P; Remington G; Mulsant B; Graff-Guerrero A
    Schizophr Res; 2015 Feb; 161(2-3):429-33. PubMed ID: 25556080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of Ferrara.
    Chiabrando G; Bianchi S; Poluzzi E; Montanaro N; Scanavacca P
    Eur J Clin Pharmacol; 2010 Jul; 66(7):661-9. PubMed ID: 20464383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study.
    Zheng L; Mack WJ; Dagerman KS; Hsiao JK; Lebowitz BD; Lyketsos CG; Stroup TS; Sultzer DL; Tariot PN; Vigen C; Schneider LS
    Am J Psychiatry; 2009 May; 166(5):583-90. PubMed ID: 19369318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of atypical antipsychotics in patients with Alzheimer's dementia. CATIE-AD-Study (Clinical Antipsychotic Trials of Intervention Effectiveness Alzheimer's Disease)].
    Förstl H
    Internist (Berl); 2007 Jun; 48(6):642-4. PubMed ID: 17497111
    [No Abstract]   [Full Text] [Related]  

  • 13. Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study.
    Rocca P; Marino F; Montemagni C; Perrone D; Bogetto F
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):622-9. PubMed ID: 18081622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
    Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Rosenheck RA; Perkins DO; Keefe RS; Davis CE; Severe J; Hsiao JK;
    Am J Psychiatry; 2006 Apr; 163(4):611-22. PubMed ID: 16585435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
    Keefe RS; Sweeney JA; Gu H; Hamer RM; Perkins DO; McEvoy JP; Lieberman JA
    Am J Psychiatry; 2007 Jul; 164(7):1061-71. PubMed ID: 17606658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
    Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
    Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis.
    Yunusa I; Rashid N; Demos GN; Mahadik BS; Abler VC; Rajagopalan K
    Adv Ther; 2022 May; 39(5):1993-2008. PubMed ID: 35247186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
    Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
    Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.
    Schneider LS; Dagerman K; Insel PS
    Am J Geriatr Psychiatry; 2006 Mar; 14(3):191-210. PubMed ID: 16505124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clozapine versus other atypical antipsychotics for schizophrenia.
    Asenjo Lobos C; Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Leucht S
    Cochrane Database Syst Rev; 2010 Nov; (11):CD006633. PubMed ID: 21069690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.